gefitinib has been researched along with 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one in 25 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one) | Trials (2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one) | Recent Studies (post-2010) (2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 4,823 | 5 | 1,810 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (44.00) | 29.6817 |
| 2010's | 11 (44.00) | 24.3611 |
| 2020's | 3 (12.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M | 1 |
| Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB | 1 |
| Guo, Y; He, J; Li, Y; Liu, M; Liu, Y; Xiao, J; Yu, W; Zhang, Q | 1 |
| Bansal, R; Malhotra, A | 1 |
| Bharate, SB; Raghuvanshi, R | 1 |
| Caballero, E; García-Cárceles, J; Gil, C; Martínez, A | 1 |
| Bakanauskas, VJ; Bernhard, EJ; Cerniglia, GJ; Feldman, MD; Goldsmith, JD; Gupta, AK; Machtay, M; McKenna, WG; Mick, R; Muschel, RJ; Rosenthal, DI; Weber, CN; Weber, RS | 1 |
| Basso, A; Moasser, MM; She, QB; Solit, D | 1 |
| Caplin, M; Friedmann, B; Hartley, JA; Hochhauser, D | 1 |
| Angelucci, A; Biordi, L; Bologna, M; Dolo, V; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Speca, S; Vicentini, C | 1 |
| Chayama, K; Kuwahara, K; Miyata, H; Sasaki, T; Serikawa, M | 1 |
| Choi, YH; Kim, GY; Kim, MO; Lee, JD; Lee, MK; Moon, DO | 1 |
| Claasen, J; Sos, ML; Staratschek-Jox, A; Thomas, RK; Wolf, J; Zander, T | 1 |
| Conaway, M; Gioeli, D; Theodorescu, D; Weber, MJ; Wu, Z | 1 |
| Deng, QF; Su, B; Zhao, YM; Zhou, CC | 1 |
| Mekada, E; Miyamoto, S; Mizushima, H; Wang, X | 1 |
| Hao, YY; Iwamori, M; Li, FF; Lin, B; Liu, DW; Liu, JJ; Qi, Y; Zhang, SL; Zhu, LC | 1 |
| Grandal, MV; Grøvdal, LM; Holst, MR; Kim, J; Knudsen, SL; van Deurs, B | 1 |
| Li, H; Schmid-Bindert, G; Su, B; Wang, D; Yang, X; Zhao, Y; Zhou, C | 1 |
| Pick, A; Wiese, M | 1 |
| Chen, J; Li, L; Luo, M; Pan, L; Qin, G; Qin, S; Yang, J; Zhang, Q | 1 |
| Du, J; Hu, H; Li, C; Li, H; Li, Y; Wang, L; Yang, H; Zhang, Z | 1 |
| Chen, Y; Dendy, M; Gruvberger-Saal, SK; Hibshoosh, H; Horlings, HM; Isola, J; Jumppanen, M; Lau, YK; Maurer, M; Memeo, L; Parsons, R; Rosen, N; Saal, LH; She, QB; Su, T; van de Vijver, MJ | 1 |
| Li, Y; Liu, W; Luo, E; Tian, L; Wang, Y; Wen, L; Wen, M; Wen, N; Yang, H; Yun, Y; Zhang, W; Zhao, L; Zhu, X | 1 |
| Fang, D; Li, HY; Liang, C; Liu, FY; Niu, J; Sun, H; Wang, X; Xie, SQ; Zhang, YD | 1 |
3 review(s) available for gefitinib and 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one
| Article | Year |
|---|---|
The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Humans; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Quinazolines | 2019 |
Therapeutic progression of quinazolines as targeted chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Enzyme Inhibitors; Humans; Molecular Structure; Neoplasms; Quinazolines | 2021 |
Kinase Inhibitors as Underexplored Antiviral Agents.
Topics: Animals; Antiviral Agents; Drug Repositioning; Humans; Protein Kinase Inhibitors; Virus Diseases; Viruses | 2022 |
1 trial(s) available for gefitinib and 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one
| Article | Year |
|---|---|
Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction.
Topics: Adult; Aged; Aged, 80 and over; Blotting, Western; Carcinoma, Squamous Cell; Cell Division; Chromones; Dose-Response Relationship, Radiation; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Immunoenzyme Techniques; Male; Middle Aged; Morpholines; Neoplasm Recurrence, Local; Neoplasm Staging; Oropharyngeal Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Prognosis; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Radiation Tolerance; ras Proteins; Signal Transduction | 2002 |
21 other study(ies) available for gefitinib and 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one
| Article | Year |
|---|---|
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2007 |
Navigating the kinome.
Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology | 2011 |
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |
Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.
Topics: Breast Neoplasms; Chromones; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Genes, Tumor Suppressor; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphoric Monoester Hydrolases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Transfection; Tumor Cells, Cultured | 2003 |
Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839).
Topics: Antineoplastic Agents; Cell Division; Cell Line, Tumor; Chromones; Cisplatin; Comet Assay; DNA Damage; DNA Repair; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Etoposide; Gefitinib; Humans; Melphalan; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Signal Transduction; Time Factors | 2004 |
Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Resistance, Neoplasm; ErbB Receptors; G1 Phase; Gefitinib; Humans; Male; Mitogen-Activated Protein Kinase Kinases; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines | 2005 |
The effects of ZD1839 (Iressa), a highly selective EGFR tyrosine kinase inhibitor, as a radiosensitiser in bile duct carcinoma cell lines.
Topics: Anthracenes; Bile Duct Neoplasms; Butadienes; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromones; Clone Cells; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; Mitogen-Activated Protein Kinases; Morpholines; Nitriles; Oncogene Protein v-akt; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Quinazolines; Radiation-Sensitizing Agents | 2006 |
Molecular mechanisms of ZD1839 (Iressa)-induced apoptosis in human leukemic U937 cells.
Topics: Antineoplastic Agents; Apoptosis; Caspase Inhibitors; Chromones; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; MAP Kinase Signaling System; Morpholines; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-bcl-2; Quinazolines; U937 Cells; X-Linked Inhibitor of Apoptosis Protein | 2007 |
Expression of signaling mediators downstream of EGF-receptor predict sensitivity to small molecule inhibitors directed against the EGF-receptor pathway.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromones; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Farnesyltranstransferase; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Signaling System; Morpholines; Phosphatidylinositols; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; ras Proteins; Sirolimus | 2008 |
Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.
Topics: Benzamides; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Chromones; ErbB Receptors; Gefitinib; Humans; Lapatinib; Male; Mitogen-Activated Protein Kinases; Morpholines; Neoplasms, Hormone-Dependent; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines | 2008 |
[Sensitivity of two cell lines with acquired resistance to gefitinib to several chemotherapeutic drugs].
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromones; Docetaxel; Drug Resistance, Neoplasm; Gefitinib; Glutamates; Guanine; Humans; Integrin beta1; Lung Neoplasms; Morpholines; Pemetrexed; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Taxoids | 2008 |
Integrin signal masks growth-promotion activity of HB-EGF in monolayer cell cultures.
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinases; Cell Adhesion; Cell Culture Techniques; Cell Proliferation; Cells, Cultured; Chromones; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Gefitinib; Heparin-binding EGF-like Growth Factor; Humans; Integrins; Intercellular Signaling Peptides and Proteins; Mice; Mice, Nude; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Signal Transduction | 2009 |
Lewis(y) antigen stimulates the growth of ovarian cancer cells via regulation of the epidermal growth factor receptor pathway.
Topics: Cell Line, Tumor; Cell Proliferation; Chromones; Cyclin-Dependent Kinase Inhibitor p27; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Flavonoids; Fucosyltransferases; Gefitinib; Humans; Lewis Blood Group Antigens; Morpholines; Ovarian Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines | 2010 |
EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
Topics: Breast Neoplasms; Butadienes; Cell Line, Tumor; Chromones; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression; Gene Expression Profiling; Humans; Imidazoles; MAP Kinase Kinase 1; Morpholines; Nitriles; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyridines; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; RNA, Messenger; Signal Transduction; Tyrphostins; Up-Regulation | 2012 |
Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Butadienes; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Chromones; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; Morpholines; Mutation; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2011 |
Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Benzimidazoles; Cell Line; Cetuximab; Chromones; Dose-Response Relationship, Drug; Drug Resistance, Multiple; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Morpholines; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Signal Transduction; Tyrphostins | 2012 |
Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Communication; Cell Line, Tumor; Chromones; Connexin 26; Connexins; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gap Junctions; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Nude; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
MicroRNA-221 targets PTEN to reduce the sensitivity of cervical cancer cells to gefitinib through the PI3K/Akt signaling pathway.
Topics: 3' Untranslated Regions; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Survival; Chromones; Enzyme Inhibitors; Female; Gefitinib; HeLa Cells; Humans; MicroRNAs; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; PTEN Phosphohydrolase; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Uterine Cervical Neoplasms | 2016 |
Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Animals; Breast Neoplasms; Chromones; Class I Phosphatidylinositol 3-Kinases; Drug Synergism; ErbB Receptors; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Mice; Middle Aged; Morpholines; Mutation; Phosphoric Monoester Hydrolases; Polyethylene Glycols; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Tissue Array Analysis; Xenograft Model Antitumor Assays | 2016 |
FOXM1 confers resistance to gefitinib in lung adenocarcinoma via a MET/AKT-dependent positive feedback loop.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Chromones; Drug Resistance, Neoplasm; Feedback, Physiological; Forkhead Box Protein M1; Gefitinib; Humans; Indoles; Lung Neoplasms; Morpholines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; RNA, Small Interfering; Signal Transduction; Sulfones | 2016 |
Suppression of epidermal growth factor receptor-mediated β-catenin nuclear accumulation enhances the anti-tumor activity of phosphoinositide 3-kinase inhibitor in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Breast Neoplasms; Cell Proliferation; Chromones; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Heterocyclic Compounds, 3-Ring; Humans; MCF-7 Cells; Morpholines; Phosphoinositide-3 Kinase Inhibitors | 2019 |